A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Clinical trial NCT04607148 · TERMINATED
Trial details
- NCT number
- NCT04607148
- Sponsor
- Genentech, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-16
- Primary completion
- 2022-11-14
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.